CPNM Avanzado Segunda Línea
- TELMA
- ETOP-CHESS
- NIVIPI BRAIN
- REPLAY
- SPLENDOUR
- PIPSeN
- DURVAST
- NIVEX
- ATEZO- BRAIN
TELMA
(GECP 18/03)
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
ETOP-CHESS
(ETOP 14-18)
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer.
NIVIPI BRAIN
(GECP 21/02)
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases.
REPLAY
(GECP 17/02)
A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non – Small Cell Lung Cancer.
SPLENDOUR
(ETOP-5–12)
A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC
PIPSeN
(CSET2014/2204_PIPSeN)
A Randomized Double-blind Phase II Trial Evaluating Maintenance Olaparib Versus Placebo in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer.
DURVAST
(GECP 16/04)
Phase II clinical study of Durvalumab (MEDI4736) in HIV-1 (Human Immunodeficiency Virus-1) positive patients with advanced solid tumors.
NIVEX
(GECP 16/05)
A Retrospective, Multicenter and Observational Study of Nivolumab Monotherapy Treatment in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV NSCLC Within the Expanded Access Program (EAP) in SPAIN.
ATEZO- BRAIN
(GECP 17/05)
Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naïve and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis.
